Nectar Lifesciences Share Price

Nectar Lifesciences Share Price

NSE: NECLIFE
|
Pharmaceuticals
|
S Cap
₹ 12.17
-₹0.14 (-1.14%)
1D
Last updated 03 Sep, 2026, 15:29 IST

Nectar Lifesciences Share Price Today

As of 4 Sep 2026, Nectar Lifesciences share price is ₹12.17. The stock opened at ₹12.15, compared to its previous close of ₹12.31. During today's trading session, Nectar Lifesciences share price moved in the range of ₹12.10 to ₹12.65, with an average price of ₹12.38 for the day. Looking at its last 52-week, the stock has touched a low of ₹9.30 and a high of ₹22.40.

₹12.10
1.14% down today
₹12.65
1D LOW
1D HIGH

Nectar Lifesciences Returns Calculator

Circuit
L
H
₹11.70
₹12.92
52-week
L
H
₹9.30
₹22.40

About Nectar Lifesciences

Nectar Lifesciences Share Price
ISIN
INE023H01027
Sector Market Cap
₹ 236.03 Cr

Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.

Nectar Lifesciences Financial Highlights

  • Revenue: Nectar Lifesciences reported revenue of ₹9.29 crore in FY26 vs ₹1.88 crore in FY25. It showed an increase of 394.15% on a yearly basis.
  • Operating Profit: Nectar Lifesciences reported an operating loss of ₹87.88 crore in FY26 vs ₹1.07 crore in FY25. It showed a decrease of 8,313.08% on a year-on-year basis.
  • Net Profit: Nectar Lifesciences reported a net loss of ₹292.89 crore in FY26 vs ₹113.68 crore in FY25. It showed a decrease of 157.64% on a yearly basis.

Nectar Lifesciences Quarterly Result Highlights

  • Nectar Lifesciences reported revenue of ₹3.36 crore in Jun 2026, compared with ₹7.58 crore in Mar 2026, representing a decrease of 55.67% on a quarter-on-quarter (QoQ) basis.
  • Nectar Lifesciences reported an operating loss of ₹24.62 crore in Jun 2026, compared with ₹56.93 crore in Mar 2026, representing an increase of 56.75% on a quarter-on-quarter (QoQ) basis.
  • Nectar Lifesciences reported a loss of ₹15.40 crore in Jun 2026, compared with ₹67.92 crore in Mar 2026, reflecting an increase of 77.33% on a QoQ basis.
  • The earnings per share (EPS) of Nectar Lifesciences stood at ₹13.40 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
51.84%
FII
0.50%
Other DII
3.74%
Retail and other
43.91%
Mutual funds
0.00%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20250.52%
Jan 20260.58%
Mar 20260.60%
Jun 20260.50%
Mkt Cap Cr
236.03
P/E
-0.96
P/B
0.41
ROE
-9.85%
D/E
0.38
ROCE
-8.75%
Div. Yield
0.00%
EPS(TTM)
-13.40
Turnover
0.01
EV/EBITDA
-0.51
Net Margin
0.00%
Op. Margin
0.00%
ROA
-39.42%
Quick Ratio
9.60
Curr. Ratio
9.50
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Nectar Lifesci. outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Nectar Lifesci. appears overvalued compared to its peers
Step 3 of 5
Earnings
Neutral
Nectar Lifesci. earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,63,791.0037.705.4713.74%0.6117.33%93.240.83%0.4810.90
Divis Laboratories2,45,081.0083.7914.6215.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,90,351.0086.8922.2825.49%1.6913.85%222.760.68%0.4958.70
Zydus Lifesciences1,14,833.0024.654.1818.59%0.3117.35%237.300.09%0.3335.38
Cipla1,14,163.0034.023.3211.27%0.0014.95%423.360.92%0.4543.52
Laurus Labs1,00,660.0092.3218.9916.77%0.4016.14%97.200.11%0.6713.72
Lupin98,431.0017.594.3523.76%0.0424.88%659.000.84%0.57129.18
Mankind Pharma98,304.7046.845.9411.74%0.3413.13%396.980.04%0.4449.37
Dr. Reddy's Laboratories96,906.3030.442.5511.07%0.1812.54%377.950.69%0.4138.68
Aurobindo Pharma95,299.8025.682.529.25%0.1911.76%394.820.24%0.3841.58

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Nectar Lifesciences Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹0.00₹1,669.97₹1,684.09₹1,523.67
Other Income₹9.29₹4.99₹14.58₹43.18
Total Revenue₹9.29₹1,674.97₹1,698.66₹1,566.85
Total Expenses₹97.17₹1,836.50₹1,680.39₹1,609.27
Profit Before Tax-₹87.88-₹161.53₹18.27-₹42.42
Tax-₹30.53-₹47.85₹13.27-₹18.24
Profit After Tax-₹57.35-₹113.68₹5.00-₹24.18
EPS - Basic-₹13.40-₹5.07₹0.22-₹1.08
EPS - Diluted-₹13.40-₹5.07₹0.22-₹1.08

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹788.91-₹161.53₹18.27-₹42.42
Income before WC changes-₹554.67-₹22.51₹155.82₹55.73
Change in Assets₹606.85₹170.62-₹44.77₹150.36
Change in Liabilities-₹400.90₹21.33₹113.63-₹72.43
Change in WC₹205.95₹191.95₹68.87₹77.93
Cash flow from Operations-₹348.72₹169.44₹224.69₹133.65
Cash flow from Investing₹1,208.15-₹41.93-₹17.03₹51.70
Cash flow from Financing-₹766.51-₹128.09-₹205.44-₹185.58
Total Cash Flow₹92.91-₹0.58₹2.23-₹0.23
Cash (Start of the year)₹19.22₹19.81₹17.58₹17.81
Cash (End of the year)₹112.14₹19.22₹19.81₹17.58

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹368.64₹809.64₹907.23₹958.03
Current Assets₹252.97₹1,237.59₹1,283.83₹1,231.18
Total Assets₹621.61₹2,047.23₹2,191.06₹2,189.21
Current Liabilities₹26.05₹1,021.54₹972.82₹890.93
Net Current Asset₹226.92₹216.05₹311.02₹340.26
Non-Current Liabilities₹13.26₹69.58₹148.99₹233.69
Equity Capital₹582.30₹956.11₹1,069.25₹1,064.60
Total Equity & Liabilities₹621.61₹2,047.23₹2,191.06₹2,189.21

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹0.00₹0.00₹1,684.09₹1,523.67
Other Income₹9.29₹1.88₹14.58₹43.18
Total Revenue₹9.29₹1.88₹1,698.66₹1,566.85
Total Expenses₹97.16₹0.81₹1,680.39₹1,607.54
Profit Before Tax-₹87.87₹1.07₹18.28-₹40.69
Tax-₹30.53₹0.38₹13.27-₹18.24
Profit After Tax-₹57.34₹0.70₹5.00-₹22.46
EPS - Basic-₹13.40-₹5.07₹0.22-₹1.00
EPS - Diluted-₹13.40-₹5.07₹0.22-₹1.00

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹788.90-₹161.53₹18.28-₹40.69
Income before WC changes-₹554.67-₹22.51₹155.83₹56.39
Change in Assets₹508.21₹170.62-₹44.77₹149.33
Change in Liabilities-₹370.90₹21.33₹113.63-₹72.35
Change in WC₹137.31₹191.95₹68.87₹76.98
Cash flow from Operations-₹417.35₹169.44₹224.69₹133.37
Cash flow from Investing₹1,205.41-₹41.93-₹17.03₹52.03
Cash flow from Financing-₹699.15-₹128.09-₹205.44-₹185.57
Total Cash Flow₹88.91-₹0.58₹2.23-₹0.17
Cash (Start of the year)₹19.22₹19.80₹17.57₹17.74
Cash (End of the year)₹108.13₹19.22₹19.80₹17.57

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹362.78₹809.65₹907.23₹958.04
Current Assets₹249.57₹1,237.58₹1,283.83₹1,231.18
Total Assets₹612.34₹2,047.23₹2,191.06₹2,189.21
Current Liabilities₹25.97₹1,021.54₹972.82₹890.93
Net Current Asset₹223.60₹216.04₹311.01₹340.25
Non-Current Liabilities₹4.07₹69.58₹148.99₹233.69
Equity Capital₹582.31₹956.11₹1,069.25₹1,064.60
Total Equity & Liabilities₹612.34₹2,047.23₹2,191.06₹2,189.21
* All values are in INR Crore
Qty
Bid
135
12.17
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 135
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
59.62
Neutral
ATR (14)
0.72
Neutral
STOCH(9,6)
57.62
Neutral
STOCH RSI (14)
56.78
Neutral
ADX(9)
25.39
Bearish
UO(9)
49.19
Neutral
ROC(12)
13.57
Bullish
WillR(14)
-37.1
Neutral
Period
Simple value
Exponential vaue
5D
12.33
12.24
10D
11.97
11.99
20D
11.36
11.6
50D
11.1
11.36
100D
11.67
11.85
Volume trend — traded volume by day
3 Sep2L
2 Sep3L
1 Sep2L
31 Aug2L
28 Aug4L
Average3L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Nectar Lifesciences Share Price
Nectar Lifesciences
Pharmaceuticals
Add Stock
Add Another

Nectar Lifesciences Share Price FAQs

Nectar Lifesciences share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837